Warren Urges FTC To Closely Scrutinize Novo Nordisk-Catalent Merger, Block if Illegal Under Antitrust Law

Press Release

“Given the proposed merger’s potential to further limit competition in the weight loss and diabetes drug markets, making it harder for patients to access these drugs, I urge FTC to closely scrutinize this acquisition and block any activity found to be illegal under antitrust law.

“I am concerned that Novo Nordisk’s merger with Catalent will give Novo Nordisk unprecedented visibility into and control over its competitor’s production capacity, costs, and business practices, and the ability to preference its own products and obstruct its competitors’ use of Catalent to produce GLP-1 drugs.

“While Novo Nordisk claims to ‘provide access to the medicines . . . to the greatest number of people living with diabetes . . . while addressing varying levels of affordability,’ the company’s actions suggest otherwise.

"As diabetes and obesity rates continue to rise — 38 percent of Americans were estimated to be prediabetic in 2021, while more than 40 percent of adults in the U.S. experience obesity — it is all the more crucial that Americans can access life-changing drugs to treat these conditions at a fair price."

Source